



Case 3

1

Baseline

- 68 yo Caucasian male complained of blurred and wavy vision for 2-3 weeks in the right eye.
- VA: 20/20
- IOP: 13
- Ocular Hx: spontaneously resolved distortion 13 years prior




2

s/p aflibercept #5



Persistent fluid s/p IV aflibercept #9
20/40

Perform PDT + combination anti-VEGF



Reduced-fluence ICG-guided PDT+IVA/Dex

3

Treatment Response

Initial aflibercept q 2 months but then pm for 4 months

1 mo s/p PDT 20/30

14 months S/P PDT 20/20

Other health problems but symptomatically stable x 2 years after 14 month visit

4

PCV in Caucasians

- More common than previously thought
 - 31.1% in Caucasians in Hawaii
 - 24.5% in patients of European ancestry in Brazil
 - 21.5% of anti-VEGF resistant patients in Switzerland
- Higher incidence of anti-VEGF resistance
 - 62.1% had persistent disease activity after three sequential anti-VEGF
- Better response to combination PDT/anti-VEGF +/- steroid

5

Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy

Cheng T. Kokame, MD, MBA,^{1,2,3,4} Takao E. deCarlo, MD,^{1,2,3,4} Kyō N. Kaneko, BS,^{2,3,4} Jae N. Omizo, BS,^{1,2} Balakrishnan Lian, BA¹

Purpose: To evaluate the prevalence of polypoidal choroidal vasculopathy (PCV) in different ethnic populations and to determine the prevalence of PCV in eyes with exudative age-related macular degeneration (AMD) that is sensitive and resistant to anti-vascular endothelial growth factor (VEGF) therapy.

OPEN ACCESS

Ophthalmology Retina

- Kokame GT, deCarlo TE, Kaneko KN, Omizo JN, Lian R. Anti-vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy. *Ophthalmology Retina* 2019; 3(9): 744-752.

6